May 2022
Shared Decision Making:
Understanding Your Immunotherapy Choices
KidneyCAN's April 2022 Town Hall event focused on immunotherapy options for patients with kidney cancer. Our panel of expert oncologists included Dr. Naomi Haas from Penn Medicine, Dr. Hans Hammers from UTSW, and Dr. Monty Pal from City of Hope, who discussed how they share the immunotherapy treatment decision-making process with their patients.

Following their discussions, the doctors took questions from patients all over the world. You can watch the full event here:
5 Things You Should Know:
Clinical Trials and Diversity
April is National Minority Health Awareness Month. The FDA explains that patients from minority communities have low rates of participation in clinical trials. This is a concern because people of different ages, races, and ethnicities may react differently to medical products or therapies.

Ensuring people from diverse backgrounds join clinical trials is key to advancing health equity. The FDA created a fact sheet with five key facts about clinical trials and additional information about diverse participation and trial access.
Report from the International Kidney Cancer Coalition:
Patient Retention in Clinical Trials
Clinical trials are the key to advancing treatments for kidney cancer. The International Kidney Cancer Coalition (IKCC) launched a pilot program to consider the patient perspective in joining a clinical trial and factors that can influence clinical trial retention.

Research has shown that kidney cancer clinical trials have lower patient retention rates compared to clinical trials for other types of cancer. This can be caused by a number of factors, including the burdens of travel, time away from home and work, cost, and side effects.
KidneyCAN participated in this project with the IKCC and is pleased to share the resulting paper.
Are you following us online? Tag @KidneyCAN
in your #kidneycancer posts!
KidneyCAN Community Spotlight:
Remembering Ralph Knapp
Earlier this month, we shared with you the sad news that Ralph Knapp, co-founder of KidneyCAN, has passed. For our Community Spotlight feature, we would like to share more of Ralph's story and insights about his experiences with kidney cancer as told by his closest friends and family.

Ralph accomplished a great deal in his sixty years, and he leaves lessons for all of us.
"I have fought the good fight, I have finished my course, I have kept the faith."
2 Timothy 4:7
KCRS22 Preview!
Meet the Featured Speakers
We're excited to share this all-star lineup for KCRS22! Our program will feature the following special speakers whose work focuses on immunology. Read on to learn how their work is accelerating cures for kidney cancer:
Drew Pardoll,
M.D., Ph.D.

Johns Hopkins
Medical Center
Bloomberg-Kimmel Institute for Cancer Immunotherapy
Suzanne Topalian, M.D.

Johns Hopkins
Medical Center
Associate Director, Bloomberg-Kimmel Institute for Cancer Immunotherapy
Andrew Sewell,

Cardiff University
Division of Infection and Immunity
Register now to hear these great speakers and more!

Patients, caregivers, clinicians, junior researchers, Industry representatives can now register for the virtual meeting.  Thanks to the generosity of our sponsors, the virtual meeting is offered FREE - no registration fee!
For fiscal year 2022, Congress appropriated $50 million for the Kidney Cancer Research Program, part of the Congressionally Directed Medical Research Programs. We have to work for this money every year through advocacy.
Save the date for our next advocacy event in August:
District Days
August 8-9, 2022
Our mission is to accelerate cures for kidney cancer. We engage in patient advocacy and power research by supporting government and industry research funding, facilitating research collaborations, and offering direct financial support for clinical and laboratory researchers with promising ideas. Our work is funded by grassroots donors from all over the United States. We can't do this without your support.
Thank you for being part of our grassroots army!
KidneyCAN is a registered 501(c)(3) nonprofit and does not receive any funding through the Congressionally Directed Medical Research Program (CDMRP) or KCRP (Kidney Cancer Research Program). KidneyCAN's work is funded entirely through donations.